title: Comparison of Efficacy of Long-term Oral Treatment with Telmisartan and Benazepril in Cats with Chronic Kidney Disease.
abstract: BACKGROUND
  The efficacy and benefits of telmisartan in cats with chronic kidney disease (CKD) have not previously been reported.
  
  
  OBJECTIVE
  Long-term treatment of cats with CKD using telmisartan decreases urine protein-to-creatinine ratio (UP/C) similar to benazepril.
  
  
  METHODS
  Two-hundred and twenty-four client-owned adult cats with CKD.
  
  
  METHODS
  Prospective, multicenter, controlled, randomized, parallel group, blinded clinical trial with noninferiority design. Cats were allocated in a 1:1 ratio to either telmisartan (1 mg/kg; n = 112) or benazepril (0.5-1.0 mg/kg; n = 112) PO q24 h. The primary endpoint was prospectively defined as the change in proteinuria (benazepril:telmisartan) based on a log transformed weighted average of UP/C change from baseline (AUC 0→t/t) as a percentage compared using a confidence interval (CI) approach. Changes of UP/C from baseline were assessed on all study days and corrected for multiple comparisons.
  
  
  RESULTS
  Telmisartan proved noninferior to benazepril in controlling proteinuria (CI, -0.035 to 0.268). At Day 180, UP/C compared to baseline in the telmisartan group was significantly lower (-0.05 ± 0.31; P = .016), whereas in the benazepril group the change (-0.02 ± 0.48) was not statistically significant (P = .136). Similar results were obtained at all assessment points with significant decrease in UP/C occurring with telmisartan but not benazepril.
  
  
  CONCLUSIONS
  Both telmisartan and benazepril were well tolerated and safe. Telmisartan proved to be noninferior to benazepril and significantly decreased proteinuria relative to baseline at all assessment points whereas benazepril did not.
authors.affiliation: Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany.
authors.forename: U
authors.initials: U
authors.lastname: Sent
authors.affiliation: Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany.
authors.forename: R
authors.initials: R
authors.lastname: Gössl
authors.affiliation: Department of Comparative Biomedical Sciences, Royal Veterinary College, London, UK.
authors.forename: J
authors.initials: J
authors.lastname: Elliott
authors.affiliation: Department of Clinical Sciences and Services, Royal Veterinary College, Herts, UK.
authors.forename: H M
authors.initials: HM
authors.lastname: Syme
authors.affiliation: Boehringer Ingelheim Animal Health GmbH, Ingelheim, Germany.
authors.forename: T
authors.initials: T
authors.lastname: Zimmering
mesh_terms: D047228:Angiotensin II Type 1 Receptor Blockers / Q000008:administration & dosage / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D000818:Animals; D001552:Benzazepines / Q000008:administration & dosage / Q000627:therapeutic use*; D001562:Benzimidazoles / Q000008:administration & dosage / Q000627:therapeutic use*; D001565:Benzoates / Q000008:administration & dosage / Q000627:therapeutic use*; D002371:Cat Diseases / Q000188:drug therapy*; D002415:Cats; D004334:Drug Administration Schedule; D005260:Female; D008297:Male; D051436:Renal Insufficiency, Chronic / Q000188:drug therapy / Q000662:veterinary*; D000077333:Telmisartan
chemical_list: D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors; D001552:Benzazepines; D001562:Benzimidazoles; D001565:Benzoates; D000077333:Telmisartan; C044946:benazepril
keywords: ACE inhibitor; Angiotensin II receptor blocker; Benazepril; Proteinuria